Volume 22, Number 1—January 2016
Dispatch
Asymptomatic Lymphogranuloma Venereum in Men who Have Sex with Men, United Kingdom
Table 2
Patient characteristics | No. (%) or median [IQR] |
||||||||
---|---|---|---|---|---|---|---|---|---|
All asymptomatic CT | Asymptomatic non-LGV CT | Asymptomatic LGV | Univariable analysis |
Multivariable analysis† |
|||||
OR (95% CI) | p value | OR (95% CI) | p value | ||||||
All patients |
429 (100.0) |
414 (96.5) |
15 (3.5) |
||||||
Clinic location, n = 429 | |||||||||
London | 333 (77.6) | 323 (78.0) | 10 (66.7) | 1 | 0.47 | ||||
Manchester | 54 (12.6) | 52 (12.6) | 2 (13.3) | 1.24 (0.26–5.83) | |||||
Brighton | 26 (6.1) | 24 (5.8) | 2 (13.3) | 2.69 (0.56–12.99) | |||||
Glasgow‡ |
16 (3.7) |
15 (3.6) |
1 (6.7) |
||||||
Infection site, n = 427 | |||||||||
Nonrectal | 129 (30.2) | 126 (30.6) | 3 (20.0) | 1 | |||||
Rectal |
298 (69.8) |
286 (69.4) |
12 (80.0) |
1.67 (0.46–6.08) |
0.44 |
||||
Multiple infection sites, n = 429 | |||||||||
No | 397 (92.5) | 383 (92.5) | 14 (93.3) | 1 | |||||
Yes |
32 (7.5) |
31 (7.5) |
1 (6.7) |
0.95 (0.12–7.48) |
0.96 |
||||
Age, y, n = 429 | 33 [27–42] | 33 [26–42] | 38 [29–44] | | |||||
18–24 | 73 (17.0) | 72 (17.4) | 1 (6.7) | 1 | 0.64 | ||||
25–34 | 172 (40.1) | 167 (40.3) | 5 (33.3) | 2.19 (0.25–19.07) | |||||
35–44 | 105 (24.5) | 99 (23.9) | 6 (40.0) | 3.72 (0.43–32.59) | |||||
>44 |
79 (18.4) |
76 (18.4) |
3 (20.0) |
2.8 (0.28–27.55) |
|||||
Ethnicity, n = 378 | |||||||||
White | 302 (79.9) | 290 (79.5) | 12 (92.3) | 1 | 0.32 | ||||
Black or Black British | 18 (4.8) | 18 (4.9) | 0 | NP | |||||
Mixed | 19 (5.0) | 19 (5.2) | 0 | NP | |||||
Asian and Asian British | 17 (4.5) | 17 (4.7) | 0 | NP | |||||
Other ethnic groups | 13 (3.4) | 13 (3.6) | 0 | NP | |||||
Unknown |
9 (2.4) |
8 (2.2) |
1 (7.7) |
3.02 (0.35–26.13) |
|||||
HIV status, n = 378 | |||||||||
Negative | 235 (62.2) | 231 (63.3) | 4 (30.8) | 1 | |||||
Positive |
143 (37.8) |
134 (36.7) |
9 (69.2) |
3.88 (1.17–12.84) |
0.03 |
3.91 (0.92–16.66) |
0.06 |
||
No. sexual partners in previous 3 mo, n = 401 | |||||||||
No. partners | 3 [1–5] | 3 [1–5] | 3 [2–5] | ||||||
0–1 | 106 (26.4) | 103 (26.7) | 3 (20.0) | 1 | 0.87 | ||||
2–5 | 207 (51.6) | 198 (51.3) | 9 (60.0) | 1.41 (0.37–5.44) | |||||
>6 |
88 (21.9) |
85 (22.0) |
3 (20.0) |
1.16 (0.23–5.90) |
|||||
Concurrent sexually transmitted infections, n = 398 | |||||||||
No | 295 (74.1) | 283 (73.7) | 12 (85.7) | 1 | |||||
Yes |
103 (25.9) |
101 (26.3) |
2 (14.3) |
0.47 (0.10–2.12) |
0.32 |
||||
STI during previous 12 mo, n = 374 | |||||||||
No | 297 (79.4) | 291 (80.4) | 6 (50.0) | 1 | |||||
Yes | 77 (20.6) | 71 (19.6) | 6 (50.0) | 4.1 (1.28–13.09) | 0.02 | 3.1 (0.87–10.99) | 0.08 |
*n values indicate number of patients for which data were available in each category. CT, Chlamydia trachomatis; LGV, lymphogranuloma venereum; No., number; IQR, interquartile range; CI, confidence interval; OR, odds ratio; NP, not performed. Blank cells indicate not applicable.
†Multivariable analysis adjusted for age and location
‡Glasgow patients were excluded from all univariable and multivariable analyses because they do not routinely report to the Genitourinary Medicine Clinic Activity Dataset.
1Additional members of the UK LGV Case-Finding Group who contributed to data collection, analysis, and manuscript review are listed at the end of this article.
Page created: December 18, 2015
Page updated: December 18, 2015
Page reviewed: December 18, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.